Clinical trial · Observational
Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Renal Tumor Project: Application of Array-Based Methods and Next Generation Sequencing to Identify Candidate Molecular Targets for High-Risk Wilms Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is studying biomarkers in tissue samples from patients with high-risk Wilms tumor. Studying samples of tissue from patients with cancer in the laboratory may help doctors to learn more about changes that occur in DNA and identify biomarkers related to cancer.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Clear Cell Sarcoma of the Kidney | Clear Cell Sarcoma of the Kidney | ONTOLOGY_EXACT | 0.98 |
| Recurrent Wilms Tumor and Other Childhood Kidney Tumors | — | UNRESOLVED | — |
| Rhabdoid Tumor of the Kidney | Rhabdoid Tumor of the Kidney | ONTOLOGY_EXACT | 0.98 |
| Stage III Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
| Stage II Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
| Stage IV Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
| Stage I Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
| Stage V Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| diagnostic laboratory biomarker analysis | Other | — | UNRESOLVED |
| DNA methylation analysis | Genetic | — | UNRESOLVED |
| gene expression analysis | Genetic | — | UNRESOLVED |
| microarray analysis | Genetic | — | UNRESOLVED |
| reverse transcriptase-polymerase chain reaction | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Biomarker (DNA methylation, gene expression, RT-PCR)
- description
- Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression analysis, DNA methylation, and genomic re-sequencing by microarray analysis-based methods, including PCR analysis, DNA methylation analysis-specific RT-PCR, and quantitative RT-PCR (reverse transcriptase-polymerase chain reaction)
- interventionNames
- Genetic: DNA methylation analysis
- Genetic: gene expression analysis
- Genetic: microarray analysis
- Genetic: reverse transcriptase-polymerase chain reaction
- Other: diagnostic laboratory biomarker analysis
Primary outcomes (3)
- measure
- Genomic gains and losses in high-risk Wilms tumor
- timeFrame
- After completion of biomarker analysis
- measure
- Transcription patterns involved in the pathogenesis of Wilms tumor
- timeFrame
- After completion of biomarker analysis
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of high-risk Wilms tumor meeting ≥ 1 of the following criteria: * Relapsed disease * Anaplastic disease * Clear cell sarcomas of the kidney * Rhabdoid tumors * Registered on NWTS-4, NWTS-5 (now COG-Q9401), or participation in AREN03B2 protocols with clinical follow-up \> 3 years * Banked frozen tumor samples and paired normal DNA available with clinical data points, including the following: * Age, race, and gender * Stage and reason for stage * Tumor weight * Associated precursor lesions (rests) * Histologic subtype * Site and time of recurrence * Days of follow-up * Time and reasons for death (e.g., tumor, toxicity, infection, or other)
References
Publications (0)
Data not yet available